drugset
drugset / Trial / NCT02514551

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

NCT02514551 ↗

Phase 2 Completed 245 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).

Timeline

Start
2015-10-12
Primary completion
2017-10-27
Completion
2018-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramucirumab Monoclonal antibody 8 mg/kg Intravenous
Subject Ramucirumab Monoclonal antibody 12 mg/kg Intravenous
Background Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications

gastric adenocarcinoma gastroesophageal junction adenocarcinoma